Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

G Alleva

Showing results (31-40 of 43) with videos related to

Pageof 5
Sort By:
Journal of Immunology (Baltimore, Md. : 1950)|September 23, 2003
Cuttine edge: diabetes-associated quantitative trait locus, Idd4, is responsible for the IL-12p40 overexpression defect in nonobese diabetic (NOD) micePedro B Simpson, Monica S Mistry, Richard A Maki, et al.
Scandinavian Journal of Immunology|September 15, 2006
Experimental autoimmune encephalomyelitis develops in CC chemokine receptor 7-deficient mice with altered T-cell responsesA Pahuja, R A Maki, P A Hevezi, et al.
The Journal of Clinical Investigation|February 13, 2001
A disease-associated cellular immune response in type 1 diabetics to an immunodominant epitope of insulinD G Alleva, P D Crowe, L Jin, et al.
Vaccine|February 18, 2014
Enhanced early innate and T cell-mediated responses in subjects immunized with Anthrax Vaccine Adsorbed Plus CPG 7909 (AV7909)Jacob T Minang, Jon R Inglefield, Andrea M Harris, et al.
Journal of Pharmacological and Toxicological Methods|March 16, 2005
A high-throughput chemotaxis assay for pharmacological characterization of chemokine receptors: Utilization of U937 monocytic cellsThomas R Ott, Anil Pahuja, Francisco M Lio, et al.
Frontiers in Immunology|March 22, 2024
An antigen-specific immunotherapeutic, AKS-107, deletes insulin-specific B cells and prevents murine autoimmune diabetesDavid G Alleva, Andrea R Delpero, Thillainaygam Sathiyaseelan, et al.
Diabetes|June 28, 2002
Immunological characterization and therapeutic activity of an altered-peptide ligand, NBI-6024, based on the immunodominant type 1 diabetes autoantigen insulin B-chain (9-23) peptideDavid G Alleva, Amitabh Gaur, Liping Jin, et al.
The Journal of Pharmacology and Experimental Therapeutics|March 12, 2005
Pharmacological characterization of CXC chemokine receptor 3 ligands and a small molecule antagonistChristopher E Heise, Anil Pahuja, Sarah C Hudson, et al.
Scandinavian Journal of Immunology|January 10, 2006
Immunomodulation in type 1 diabetes by NBI-6024, an altered peptide ligand of the insulin B epitopeD G Alleva, R A Maki, A L Putnam, et al.
Vaccine|October 13, 2021
Development of an IgG-Fc fusion COVID-19 subunit vaccine, AKS-452David G Alleva, Andrea R Delpero, Melanie M Scully, et al.
Pageof 5

Showing results (31-40 of 43) with videos related to

Sort By:
Pageof 5
Journal of Immunology (Baltimore, Md. : 1950)|September 23, 2003
Cuttine edge: diabetes-associated quantitative trait locus, Idd4, is responsible for the IL-12p40 overexpression defect in nonobese diabetic (NOD) micePedro B Simpson, Monica S Mistry, Richard A Maki, et al.
Scandinavian Journal of Immunology|September 15, 2006
Experimental autoimmune encephalomyelitis develops in CC chemokine receptor 7-deficient mice with altered T-cell responsesA Pahuja, R A Maki, P A Hevezi, et al.
The Journal of Clinical Investigation|February 13, 2001
A disease-associated cellular immune response in type 1 diabetics to an immunodominant epitope of insulinD G Alleva, P D Crowe, L Jin, et al.
Vaccine|February 18, 2014
Enhanced early innate and T cell-mediated responses in subjects immunized with Anthrax Vaccine Adsorbed Plus CPG 7909 (AV7909)Jacob T Minang, Jon R Inglefield, Andrea M Harris, et al.
Journal of Pharmacological and Toxicological Methods|March 16, 2005
A high-throughput chemotaxis assay for pharmacological characterization of chemokine receptors: Utilization of U937 monocytic cellsThomas R Ott, Anil Pahuja, Francisco M Lio, et al.
Frontiers in Immunology|March 22, 2024
An antigen-specific immunotherapeutic, AKS-107, deletes insulin-specific B cells and prevents murine autoimmune diabetesDavid G Alleva, Andrea R Delpero, Thillainaygam Sathiyaseelan, et al.
Diabetes|June 28, 2002
Immunological characterization and therapeutic activity of an altered-peptide ligand, NBI-6024, based on the immunodominant type 1 diabetes autoantigen insulin B-chain (9-23) peptideDavid G Alleva, Amitabh Gaur, Liping Jin, et al.
The Journal of Pharmacology and Experimental Therapeutics|March 12, 2005
Pharmacological characterization of CXC chemokine receptor 3 ligands and a small molecule antagonistChristopher E Heise, Anil Pahuja, Sarah C Hudson, et al.
Scandinavian Journal of Immunology|January 10, 2006
Immunomodulation in type 1 diabetes by NBI-6024, an altered peptide ligand of the insulin B epitopeD G Alleva, R A Maki, A L Putnam, et al.
Vaccine|October 13, 2021
Development of an IgG-Fc fusion COVID-19 subunit vaccine, AKS-452David G Alleva, Andrea R Delpero, Melanie M Scully, et al.
Pageof 5